Antifungal susceptibility testing of yeasts: a brief overview.
Antifungal susceptibility testing of yeasts has lacked reproducibility because of the absence of universally accepted guidelines. The major sources of variation in susceptibility testing have been attributed to the choice of medium and pH, inoculum preparation and size, incubation temperature and time, and end-point criteria. These parameters have been addressed by the National Committee for Clinical Laboratory Standards (NCCLS) Subcommittee on Antifungal Susceptibility Testing, and proposed guidelines have recently been published. Although major advances in antifungal susceptibility testing have been achieved, particularly through the efforts of the NCCLS subcommittee, the results of studies to date do not support a correlation between the results of in vitro susceptibility testing and in vivo response. Routine antifungal susceptibility testing of yeasts should therefore be discouraged until the methodology is standardized such that it predicts clinical outcome.
Sheehan
D J
DJ
Roerig Division, Pfizer Inc., New York, New York 10017-5755.
Espinel-Ingroff
A
A
Moore
L S
LS
Webb
C D
CD
D000935:Antifungal Agents / Q000494:pharmacology*; D017408:Guidelines as Topic; D008826:Microbial Sensitivity Tests; D015003:Yeasts / Q000187:drug effects*
D000935:Antifungal Agents